ArticleBreast cancer research and treatment2017
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Clinicopathological features and impact on surgical axillary management of encapsulated papillary carcinoma of the breast.Discover oncology · 2026Article
- Limits of substitution and context-dependent selective omission of Oncotype DX recurrence score testing.Breast cancer (Tokyo, Japan) · 2026Review
- Invasive Solid Papillary Carcinoma of the Breast Initially Diagnosed as Invasive Ductal Carcinoma: A Case Report.Surgical case reports · 2026Article
- Clinical Usefulness of a Multigene Testing in Patients with Special Histologic Type Breast Cancer.Yonsei medical journal · 2025Article
- Clinical and imaging characteristics of encapsulated papillary carcinoma: a comparative analysis with intraductal papilloma.World journal of surgical oncology · 2025Article
- Article
- Breast Cancer Subtypes: Clinicopathologic Features and Treatment Considerations.Current breast cancer reports · 2024Article
- Impact of reactive changes on multigene testing: histopathologic analysis of low-grade breast cancers with high-risk 21-gene recurrence scores.Breast cancer research and treatment · 2024Article
- Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions.Current oncology reports · 2023Review
- Papillary lesions of the breast.Virchows Archiv : an international journal of pathology · 2022Review
- Oncotype DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma.Oncology letters · 2021Article
- Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.American journal of cancer research · 2021Article
- Overall Survival in Patients with Mucinous Carcinoma of Breast: A Population-Based Study.International journal of general medicine · 2021Article
- Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.Annals of surgical oncology · 2018Article
- Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study.Journal of Cancer · 2018Article
- The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes.Frontiers in genetics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
background/purposeThe 21-gene recurrence score (RS) assay predicts the likelihood of distant recurrence and chemotherapy benefit in early-stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. Data on the RS of special histologic subtypes of invasive breast carcinoma with favorable prognosis are limited.
methodsWe reviewed our institutional database to identify patients with special histologic subtypes of breast cancer associated with favorable prognosis and available RS results. Our cohort consists of fifty-seven women: thirty-three patients with pure mucinous carcinoma (MC), ten with tubular carcinoma (TC), nine with encapsulated papillary carcinoma (EPC), and five with solid papillary carcinoma (SPC).
resultsMost (44/57, 77.2%) carcinomas had low RS (≤17), and none had high RS (≥31). All EPCs had low RS, but other subtypes had RS 18-30. Higher RS was associated with lower progesterone receptor (PR) expression by immunohistochemistry and lower PR mRNA scores (P ≤ 0.007). No morphologic feature (tumor grade, biopsy site changes, cellular stroma, inflammatory cells) was associated with RS ≥ 18. At a median follow-up of 40 months, the distant recurrence-free survival was 100%. One patient with SPC developed locoregional recurrence at 22 months.
conclusionsAs the largest series to date, our study raises the question of whether the RS assay is necessary for breast cancers with favorable histology. Reflex testing of node-negative, ER+/HER2- breast cancers may be deferred for these special histologic subtypes, emphasizing the need for multidisciplinary discussions between breast pathologists and other members of the breast cancer team.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.